ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion recommending the granting of EU marketing authorisation for ECOVAXXIN® MS, a poultry vaccine against Mycoplasma synoviae.

Based on the CVMP’s Positive Opinion, the EMA is expected to issue a marketing authorisation during the first quarter of 2026, and ECO Animal Health anticipates making ECOVAXXIN® MS commercially available in the European Union in the second half of 2026.

ECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions caused by Mycoplasma synoviae infections. Air-sac and foot-pad lesions cause economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.

ECO Animal Health expects to submit additional geographic marketing authorisation requests for ECOVAXXIN® MS, as well as submissions for further vaccine products in its R&D pipeline, during the next 12 months.

David Hallas, Chief Executive Officer of ECO Animal Health, said: “We are delighted to have received a Positive Opinion from the CVMP for ECOVAXXIN MS. This significant milestone paves the way for a  mid-2026 EU launch for this innovative vaccine product, in-line with our prior guidance.

“This marks an exciting time for the Company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO’s next phase of growth. I’d like to thank our R&D, regulatory, marketing, and technical teams for their hard work in getting us to this point and look forward to updating the market on our continued progress.”